Reduction of Nosocomial Vancomycin -Resistant Enterococci (VRE) Colonization and Infection by Active Surveillance and Intervention of Infection Control
Reduction of Nosocomial VRE Colonization and Infection by Active Surveillance and Intervention of Infection Control (no)
1 other identifier
observational
80
1 country
1
Brief Summary
Vancomycin -resistant enterococci(VRE) has emerged as one of the most common nosocomial pathogen of health-care associated infection since 1988. Although the new antimicrobial agents such as Tigecycline , Daptomycin, Linezolid have clinically effectiveness for the treatment of VRE, but there was not appropriate drugs for eradicating the colonization of VRE. So the active surveillance and strict contact precaution are the best methods for VRE colonization and transmission. This is a one year study program, we select a unit as the study site. First month (January) is the prepare period. Therefore , we collect 3 months (from February to April) baseline data, then interrupted one month(May) for the health care worker's infection control education. Then the intervention period are three months (from June to August), and the last four months(from September to December) are the analysis and evaluation period. In the baseline period, we only do the patient's active surveillance and environmental culture. In the intervention period, beside the patient's active surveillance and environmental culture, we add contact precaution as the infection control method. If patient has VRE infection, we prescribe appropriate antibiotic therapy until the culture result proved no growth of VRE. The aim of this study is to compare and analyze these two period (baseline period and intervention period) for understanding the transmission, risk factors and carriage rate of VRE, as the important guidelines for the VRE infection control in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2010
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 12, 2010
CompletedFirst Posted
Study publicly available on registry
September 14, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2011
CompletedMarch 16, 2011
March 1, 2011
5 months
September 12, 2010
March 14, 2011
Conditions
Keywords
Eligibility Criteria
patients admitted to RCC unit , and these patients received active surveillance of VRE colinization
You may qualify if:
- all patients admitted to RCC unit
You may not qualify if:
- if the patients or family refused the exam of anal swab .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Taipei Medical University-WanFang Hospital
Taipei, Taiwan
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Wen-Sen Lee
Taipei Medical University WanFang Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 12, 2010
First Posted
September 14, 2010
Study Start
April 1, 2010
Primary Completion
September 1, 2010
Study Completion
February 1, 2011
Last Updated
March 16, 2011
Record last verified: 2011-03